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Abstract:
Background: The effect of the agonism on g-aminobutyric acid (GABA) receptors was studied within medial prefrontal cortex
(mPFC), amygdala (AMY) and ventral hipocampus (VH) in the plus-maze test in male rats bilaterally cannulated. These structures
send glutamatergic projections to the nucleus accumbens septi (NAS), in which interaction and integration between these afferent
pathways has been described. In a previous study of our group, blockade of glutamatergic transmission within NAS induced
an anxiolytic like effect.
Methods: Three rat groups received either saline or dipotassium chlorazepate (1 or 2 µg/1 µl solution) 15 min before testing. Time
spent in the open arms (TSOA), time per entry (TPE), extreme arrivals (EA), open and closed arms entries (OAE, CAE) and relation-
ship between open- and closed-arms quotient (OCAQ) were recorded.
Results: In the AMY injected group TSOA, OAE and EA were increased by the higher doses of dipotassium chlorazepate (p < 0.01).
In the mPFC, TPE was decreased by both doses (p < 0.05). Injection within ventral hippocampus (VH) decreased TSOA, OAE and
OCAQ with lower doses (p < 0.05). When the three studied saline groups were compared, TSOA, OAE, EA and OCAQ were en-
hanced in the VH group when compared to mPFC and AMY (p < 0.001). Insertion of inner canula (p < 0.001, p < 0.01, p < 0.01) and
saline injection showed an increasing significant difference (p < 0.001 in all cases) with the action of guide cannula alone within VH
in TSOA, OAE and EA.
Conclusion: We conclude that the injection of dipotassium chlorazepate has a differential effect depending of the brain area, leading
to facilitatory and inhibitory effects on anxiety processing.
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Introduction
Amygdala (AMY) has been classically related to anxi-
ety [26, 42, 58]. Its role has been highlighted in the re-
sponse to acute [56] as well as chronic [59] stress.
However, some additional structures and systems ap-
pear to modulate or participate in anxiety processes
[10, 55, 58]. It is the case of nucleus accumbens septi
(NAS) that has been involved in anxiety processes by
us and another group [38, 44, 45]. Glutamatergic trans-
mission within NAS appears to be a key to understand
this modulation [44, 45]. It has been postulated that
hippocampus (Hip) exerts a facilitatory and modula-
tory effect on NAS afferents from AMY and prefrontal
cortex (PFC) that converges in NAS sending glutama-
tergic projections [28, 29]. Ventral hippocampus (VH)
has been pointed as the involved substructure [5–7]. It
is relevant to explain the action of VH gating prefrontal
impulses on NAS, leading or not to goal directed be-
haviors, but also to explain emotional driving, dis-
rupted in schizophrenia [28]. A similar role could be
supposed in the case of PFC since recently, it has been
observed that under special conditions PFC could also
drive sustained up states in NAS [33].
In humans, an important number of recent studies
have focused on several structures involved in a wide
range of anxiety disorders [9, 60, 63], even in struc-
tures classically linked to cognitive functions, like PFC
[1]. In this way, recent neuroimage techniques have
implicated some NAS projecting structures, like AMY,
medial prefrontal cortex (mPFC), and Hip in post trau-
matic stress disorder (PTSD) as related brain substrates
[60]. Interestingly, these structures exert interactions
within the NAS, and they have been studied in schizo-
phrenia models [28, 29]. Recent findings appear to
show that these interactions have an important role in
various pathologies, and may be they could explain
some phenomenon in normal anxiety processing.
A correlation has been proposed between severity in
PTSD and AMY responsiveness, and during sympto-
matic states it appears to be very clear. The processing
of trauma-unrelated affective information appears to
produce also relevant modifications. The mPFC influ-
ence appears to be less important, and its responsive-
ness lowered during symptomatic states [60]. These
evidences could be suggesting an interactive balance
between both structures that has been reported in previ-
ous electrophysiological studies [28, 29, 49–52]. Fur-
thermore, mPFC hypofunction has been proposed as
underlying difficulties in emotional cognitive tasks
performance, and it has been correlated to anatomic
and functional Hip disorders in PTSD patients [60].
Other disorders in emotional cues management are
present in schizophrenia, and a Hip dysfunction has
beenproposed as its cause [28, 29, 51].
Acquisition and extinction have been widely studied
in animal models leading to some interesting findings
in anxiety therapy starting from conditioned fear. Neu-
roimaging studies during exposition to emotional am-
biguous stimuli have claimed the attention about the
relevance of an interaction between AMY and PFC
functioning as a whole circuitry, leading to new possi-
ble treatment schedules [9]. The perception and the en-
coding of arousing material appear to activate some
parts of the PFC that could be exerting a modulating
function, suggesting its possible role under stress con-
ditions and mainly during retrieval [63]. Furthermore,
an increased activity of both AMY and Hip has been
reported in situations of encoding and consolidation of
highly emotive, dangerous or stressor situations, sug-
gesting the relevance of these memory related struc-
tures in these kinds of events [63]. In the same way,
stress mediators, like corticotrophin releasing hormone
(CRH), that have a significant anxiogenic effect when
were injected to rats [22], exert their anxiogenic action
within AMY [20]. Anxiety could disrupt attention and
perception, mainly registering potential indicators of
risk or danger, leading to misunderstandings in the in-
terpretation of expressions, suggesting its influence in
cognitive processes [9].
Present study aims to a comprehensive approach of
brain dynamics in anxiety situations. Additionally, it
is oriented to understand how the benzodiazepines,
acting in some brain areas, exert different effects that
are overlapped in the systemic use of these drugs. It
has been proposed that philogenetically higher struc-
tures appear to have different sensitivity and response
to depressor drugs. The purpose of the present study
is to delimitate the specific behavioral patterns in-
duced by the action of benzodiazepines injection in
different brain nuclei related to anxiety.
Materials and Methods
Animals
Male rats from a Holtzman-derived colony aged 90
days and weighing 240–290 g were used (n = 90).
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They were maintained under controlled temperature
conditions (22–24°C) and lighting (lights on from
05.00 to 19.00 h). All tests were conducted under the
light cycle. Standard rat chow and water were freely
available.
Bioethicalconsiderations
The animal’s housing and experimental procedures
were carried on following project approval criteria of
the National University of Cuyo, accordingly to the
guidelines set by European Community Council (Di-
rective 86/609/EEC), to the bioethical rules estab-
lished by the Faculty of Medicine of the National Uni-
versity of Cuyo, and to Argentine law.
Surgery
Animals were anesthetized with ether (Andes Labora-
tories, Mendoza, Argentina) and stereotaxically im-
planted with bilateral stainless steel cannulae into the
Amy, the mPFC and the VH. The cannulae were dou-
ble barreled and the set was composed of an outer
guiding cannula stainless steel tubing (23 gauge,
15 mm in length), provided with a removable stylet
(30 gauge, 15 mm in length) to avoid its obstruction.
Cannulae were fixed to the skull using a screw and
dental acrylic (Subiton, Argentina), as in previous
studies [4, 42, 44, 45]. Coordinates for Amy in respect
to bregma were: A = –1 mm; L = ± 4.5 mm; V = –6.7 mm;
for mPFC were: A = + 4 mm; L = ± 1 mm; V = –2.5 mm;
for VH were: A = –3.6 mm; L = ± 4.5 mm; V = –4 mm.
After surgery, rats were housed individually and main-
tained undisturbed for a week recovery period.
Apparatus
The plus-maze was made of wood and consisted of
two open arms, 50 × 10 cm (length per wide), and two
enclosed arms 50 × 10 × 50 cm (length per wide per
height), arranged such that the two arms of each type
were opposite to each other. The maze was elevated
to a height of 50 cm. The room was illuminated by
a 60 W bulb 1.5 m above the apparatus.
Drug
Dipotassium chlorazepate for use in humans was used
(kindly provided by El Puente Pharmacy, Mendoza,
Argentina). This benzodiazepine, a dipotassium salt,
was elected due to its water and saline solution solu-
bility.
Experimental procedure and treatment
Animals were injected under gentle manual restraint
15 min before testing. A 30 gauge, 17 mm long stain-
less steel injection cannula (dimensioned to precisely
reach the goal area) attached to a 10 µl microsyringe
(Hamilton) was introduced into the guide cannula. Vol-
umes of 1 µl solution were gradually injected over
1 min periods into both the left and right brain structure.
Volume was designed aiming to reach the whole studied
structure. The injection cannulae were left in place for
an additional 1 min to allow for diffusion. The rats were
placed individually in the center of the plus-maze appa-
ratus, facing to the open arm, and allowed 5 min for free
exploration. All the experiments were carried out be-
tween 08.00 and 12.00 h (light cycle).
According to previous works, we measured the
time spent in the open arms (TSOA), time per entry
(TPE, quotient between time spent in the open arms
divided by the number of entries to open arms) [13,
38, 42, 44, 45], open and closed arms entries (OAE
and CAE, respectively [19]; arm entry defined as all
four paws into an arm), relationship between open
and closed arms entries (OCAQ, open/closed arms
quotient), and extreme arrivals (EA, defined as
number of times the rat reaches the end of an open
arms).
Experiment 1
Rats were bilaterally injected under gentle manual re-
straint bilaterally in AMY with either saline (1 µl) or
dipotassium chlorazepate (1 and 2 µg/1 µl) 15 min be-
fore testing. According to previous studies [13, 24,
42, 44], we measured TSOA, TPE, OAE, CAE,
OCAQ and EA.
Experiment 2
Rats were injected bilaterally in mPFC with either
saline (1 µl) or dipotassium chlorazepate (1 and
2 µg/1 µl) 15 min before test, and the experiment fol-
lowed the same routine that experiment 1.
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Experiment3
Rats were injected bilaterally in Hip with either saline
(1 µl) or dipotassium chlorazepate (1 and 2 µg/1 µl)
15 min before the test, with the same procedure as in
previous experiments.
Experiment 4
The saline groups of previous experiments were sta-
tistically compared, aiming to verify or exclude possi-
ble differences between controls, and search for its
corresponding meaning.
Experiment 5
Rats bilaterally implanted in VH were systematically
studied, in three different conditions. In the first case,
a condition of guide cannula chronic placement with
injection-like handling; in the second case, a guide
cannula chronic placement was performed, with acute
insertion of the injection cannula, and in the third
case, the guide cannula chronic placement with acute
placement of injection cannula condition was fol-
lowed by saline injection (1 µl). All procedures were
carried on 15 min before test.
Histological analysis
After the experiments, rats were euthanized with
overdose of ether and injected with saturated methyl-
ene blue solution (1 µl) through the cannula. Brains
were removed from the skull and fixed in 20% forma-
lin solution. The fixed brains were sectioned and ex-
amined with a 10× magnifying lens and the sections
containing the injection sites were saved. Microscopic
inspection of these sections served to ascertain the lo-
cation of the cannula that was transferred to standard
sections taken from a brain atlas [53]. We only report
statistics data for those rats with correct placements of
cannulae. The compromise of AMY (experiment 1,
Fig. 1), PFC (experiment 2, Fig. 3), and VH (experi-
ments 3 and 5, Fig. 5) in the diffusion area of the
methylene blue solution diffusion was checked in all
cases.
Statistical data analysis
The Kolmogorov Smirnov test was used to ascertain
parametric distribution of data. One way ANOVA fol-
lowed by Dunnett’s post-hoc test was used. In all
cases, a p < 0.05 (two tailed) was considered signifi-
cant. The results are reported as the means ± standard
error of the mean (SEM, n = 14–20 for each group).
Results
Experiment 1
When saline or dipotassium chlorazepate were
injected within AMY (Fig. 1), TSOA was modified by
treatment [F (2, 47) = 5.085, p = 0.0100], showing
a significant increase with the higher dose of dipotas-
sium chlorazepate (2 µg/1 µl, p < 0.01, Fig. 2, top
left). OAE were also modified by treatment [F (2, 47)
= 5.508, p = 0.0071], and increased by the higher dose
of dipotassium chlorazepate (2 µg/1 µl, p < 0.01,
Fig. 2, top right). A modification by treatment was
also observed in the case of EA [F (2, 47) = 4.862, p =
0.0120], and a significant increase was observed also
with the higher dipotassium chlorazepate dose (2 µg/
1 µl, p < 0.01, Fig. 2, bottom).
Experiment 2
When saline or dipotassium chlorazepate were in-
jected within mPFC (Fig. 3), only TPE was modified
by the treatment [F (2, 42) = 4.179; p = 0.0221], with
a significant decrease induced by both doses of the
drug (1 and 2 µg/1 µl, p < 0.05, Fig. 4).
Experiment 3
When saline or dipotassium chlorazepate were
injected within VH (Fig. 5), TSOA was modified by
treatment [F (2, 43) = 3.777; p = 0.0308], and
decreased by the lower dipotassium chlorazepate dose
(1 µg/1 µl, p < 0.05, Fig. 6, top left). OAE were modi-
fied by treatment [F (2, 43) = 3.580; p = 0.0365] and
also decreased by the lower dose (1 µg/1 µl, p < 0.05,
Fig. 6, top right). OCAQ was modified by treatment
[F (2, 43) = 4.252; p = 0.0206] and, again, decreased
only by the lower dose (1 µg/1 µl, p < 0.05, Fig. 6,
bottom).
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Experiment4
When a comparison was made between saline groups of
all the areas here studied (mPFC, AMY, HV), TSOA
[F (2, 41) = 25.01; p < 0.0001, Fig. 7, top left], OAE
[F (2, 41) = 19.26; p < 0.0001, Fig. 7, top right], EA
[F (2, 41 = 16.28; p < 0.0001, Fig. 7, bottom left], and
OCAQ [F (2, 41) = 11.82; p < 0.0001, Fig. 7, bottom
right] were modified by treatment, with highly significant
increases for VH injections (p < 0.001 for all cases).
Experiment 5
When a comparison was made within the VH between
implanted cannula, inner injection cannula placement
and saline injection, TSOA was modified by the treat-
ment [F (2, 35) = 11.14; p = 0.0002], showing an in-
crease induced by the mere acute introduction of this
inner cannula but also by acute saline injection
through the inner cannula (p < 0.001 for both groups,
Fig. 8, top left). OAE were modified by the treatment
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Fig. 2. Behavioral profile displayed by
rats injected into the AMY with saline
(1 µl), or dipotassium chlorazepate
(Chl, 1.0 and 2.0 µg/1 µl). On the top
left, time spent in the open arms
(TSOA); top right, open arms entries
(OAE); bottom left, extreme arrivals
(EA). Results are reported as the mean
± standard error of the mean (SEM)
(n = 1520 rats, ** p < 0.01)
Fig. 1. Schematic representation
of histology of rats used in the plus
maze test injected within AMY.
Frontal brain sections are showing
the location of the injection site in a
schematic representation of AMY
diffusion area [51]
[F (2, 35) = 10.32; p = 0.0003], and increased by the
location of the inner cannula and the saline injection
(p < 0.01 and p < 0.001, respectively, Fig. 8, top
right). EA were modified by the treatment [F (2, 35) =
9.538; p = 0.0005] and increased again by the acute
location of the inner cannula and acute saline injec-
tion (p < 0.01 and p < 0.001, respectively, Fig. 8, bot-
tom).
Discussion
In the present study, we observed that in the first ex-
periment an increase in several parameters was ob-
served when dipotassium chlorazepate was injected
within AMY (Fig. 2). In this way, TSOA, OAE and
EA reached clear levels of statistical significance (p <
0.01 for all). The effect was mainly observed with the
higher dose, but not with the lower one, even when
a dose response relation was here observed. The fact
that TSOA was increased, but not the TPE could be
considered related to motor variables, since the in-
crease in the time could be more related to an increase
in open arm visits than an increase in the time em-
ployed in each visit. The fact that also OAE and EA
were increased with the higher dose could allow us to
think that AMY benzodiazepine effect could be more
related to a disinhibitory action than typical and spe-
cific anxiolytic effect. This precise effect has been
postulated to be related to an increase in TPE [13, 38,
42, 44]. However, an increase in locomotor activity as
an anxiolytic collateral parameter could not be ruled
out. The fact that a dose response curve was not pres-
ent could allow to suppose that here AMY is acting in
an “all or nothing” manner. It may be that the whole
AMY could be acting through its action on NAS, in
which we have observed actually an increase in TPE
[42, 44], as we have also observed injecting intra ven-
tricular GABAergic agonist compounds [38]. These
NAS afferences appear to integrate the affective fa-
cilitation, given by AMY, with the goal directed mo-
tor plans, given by the PFC, and the contextual con-
straints, integrated by Hip [28, 50]. A disturbance in
these circuitries has been postulated as the neural sub-
strate of schizophrenic disorders by previous studies
[28]and recent findings of our group [4].
In the second experiment, the benzodiazepine in-
jection within mPFC decreases only TPE (Fig. 4, p <
0.05 for both doses). The fact that both doses clearly
modified this parameter could be an argument about
the higher sensibility of this zone to the depressive
benzodiazepines action. Following the same previ-
ously mentioned schedule [28], the multiple motor
plans given by the prefrontal cortex, and here inter-
fered by benzodiazepines, could explain the decrease
of the TPE, as a stereotyped behavior without perma-
nence guided for search finality. However, an addi-
tional explanation regarding anxiety increase cannot
be ruled out. Recently, a mechanism of prefrontal
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Fig. 4. Time per entry (TPE) of rats injected into the medial prefrontal
cortex (mPFC) with saline (1 µl), or dipotassium chlorazepate (Chl,
1.0 and 2.0 µg/1 µl). Results are reported as the mean ± standard
error of the mean (SEM) (n = 1416 rats, * p < 0.05)
Fig. 3. Schematic representation of histology of rats used in the plus
maze test injected within medial prefrontal cortex (mPFC). Frontal
brain sections are showing the location of the injection site in a sche-
matic representation of diffusion area [51]
down regulation of the AMY has been proposed. In
this way, GABAergic intercalated cells (ITC) are acti-
vated through glutamatergic projections from mPFC,
and these ITC inhibit the central medial nucleus of the
AMY [9, 54]. An alternative proposed pathway in-
volves glutamatergic projections from mPFC to baso-
lateral AMY exciting GABAergic interneurons [9,
30]. In present results, since a stimulation of mPFC
has a decremental effect on central AMY, a decrease
of mPFC influence induced by GABAergic depres-
sion could be reflected by an increase of AMY excita-
tory influences. By this way, intra-accumbens and
extra-accumbens pathways would be involved in this
interaction.
In the case of the injection within VH (Fig. 6),
some unexpected results were found. Firstly, it was
shown the high level of TSOA of the saline group.
This fact led us to additional experiments here de-
scribed, i.e., the saline groups comparison and the
cannulae and saline injection per se, without any
drug. Curiously, starting from these elevated saline
basal levels, the effect was the inverse than it could be
expected in other nuclei, such as AMY. A significant
decrease was observed with the lower dose (p < 0.05),
with an important tendency with the higher dose, that
was not, actually, different from the other. This effect
appears to be symmetrically inversed when compared
to the finding obtained with AMY injections, and par-
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Fig. 6. Time spent in the open arms
(TSOA), open arms entries (OAE) and
open/closed arms quotient (OCAQ) of
rats injected into the ventral hippo-
campus (VH) with saline (1 µl), or dipo-
tassium chlorazepate (Chl, 1.0 and
2.0 µg/1 µl). Results are reported as
the mean ± standard error of the mean
(SEM) (n = 1416 rats, * p < 0.05)
Fig. 5. Schematic representation of
histology of rats used in the plus maze
test injected within ventral hippocam-
pus (VH). Frontal brain sections are
showing the location of the injection
site in a schematic representation of
diffusion area [51]
allel to those observed in the case of mPFC. The syn-
ergic activity of Hip and PFC has been well described
in some conditions [28, 29]. The decrease in OAE and
OCAQ appears to run in the same way in the case of
both structures. The first parameter could be indicat-
ing inhibitory effects and the second an aversive ef-
fect of open arms. This effects could be interfering
AMY projections to NAS [28, 29], that lead to a de-
creasein these parameters.
As a fourth experiment (Fig. 7), saline groups dif-
ferences of the previous three experiments were com-
pared aiming to verify if they were or were not sig-
nificant, taking into account high values observed in
saline group in experiment 3 (TSOA, OAE and
OCAQ). Interestingly, saline injection into the VH led
us to observe that TSOA, OAE, EA and OCAQ were
clearly increased by VH saline injections when com-
pared to AMY and mPFC (p < 0.001 for all cases,
Fig. 7). This very clear effect appears to indicate
a high susceptibility of VH to the effectuated manipu-
lations. Curiously, in the previous experiment, three
of the four parameters here studied showed a lowering
response to benzodiazepines within VH, starting from
high saline injection values when compared to other
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Fig. 8. Time spent in the open arms,
open arms entries and extreme arri-
vals of rats with cannula, no injection,
with cannulae implanted within ventral
hippocampus (Hip, only guide cannu-
lae) but not injected, and rats injected
within Hip with saline injection (1 µl).
Results are reported as the mean
± standard error of the mean (SEM)
(n = 1416 rats, ** p < 0.01, *** p <
0.001)
Fig. 7. Comparison of the effects in-
duced by saline injections within
mPFC, AMY and VH. Time spent in the
open arms (TSOA), open arms entries
(OAE), extreme arrivals (EA) and
open/closed arms quotient (OCAQ) of
rats injected with saline (saline groups,
1 µl). Results are reported as the mean
± standard error of the mean (SEM)
(n = 1416 rats, *** p < 0.001)
areas. It is the case of TSOA, OAE and the OCAQ
(Fig. 6). These parameters appear to be selectively in-
fluenced by VH treatments. In this fourth experiment,
the high values obtained in TSOA, OAE, EA and
OCAQ could be interpreted as the behavioral effect of
an increase in VH inputs into NAS, with an anxio-
lytic-like manifestation. In this case, VH afferent pro-
jections to NAS could be blocking anxiogenic inputs,
such as those coming from AMY. Aiming to see if this
anxiolytic-like effect could be attributed to acute VH
tissue irritation, an additional experiment was de-
signed, comparing the chronic cannulae placement
with two potential irritation treatments: acute injec-
tion cannulae placement and acute injection cannulae
placement followed by saline injection. For this rea-
son,the fifth experiment was designed.
In the fifth experiment, a comparison was made be-
tween an implanted cannula group, an implanted can-
nula group with acute inner cannula placement, and
an implanted cannula with acute saline injection
within the VH through an inner cannula placement
(Fig. 8), aiming to see if acute tissue irritation has an
effect on anxiety. By this way, TSOA, OAE, EA and
OCAQ were increased in a highly significant manner
by the introduction of this inner cannula but also by
saline injection through the inner cannula (Fig. 8). By
this manner, results are congruent with an anxiolytic-
like effect due to acute VH tissue irritation. The de-
crease in TSOA, OAE, and OCAQ in the third experi-
ment could be explained, facing to these last evi-
dences, as a decrease of anxiolytic like effect due to
VH irritation, because of the inhibitory effects that di-
potassium chlorazepate exerts within VH tissue.
Finally, it is interesting to remark that closed arms
entries, classically linked to an increase in locomotor
activity [19], were not modified by any treatment in
all these experiments, suggesting a specific effect not
strictly related to motor variables. The difference be-
tween anxiolytic effect and unspecific actions has
been signaled. In some animal models this property
has been designed as “behavioral disinhibition” [41].
Anxiolytic treatments appear to facilitate this effect in
some models, and it could be considered as a collat-
eral effect of them. In the mice, chlordiazepoxide and
diazepam have an effect in exploration in different
tests, like hole-board, and in two-chambered appara-
tus; furthermore, they exert a disinhibitory action on
social interaction in aversive conditions (high light)
and another anxiety tests [14]. In our present condi-
tions, these effects have not masked our results, since
the main locomotor variable, the closed arm entries,
was not here influenced. When both variables (entries
to the open and closed arms) were considered together
there was no significant difference between groups
injected with saline or benzodiazepine (data not
shown).
Globally considered (see Tab. 1), all these findings
could be pointing that irritation of VH could be pro-
ducing a discharge increase that leads to a decrease in
AMY influences on NAS. In the same way, VH inhi-
bition by benzodiazepine leads to a decrease in most
of the parameters studied, and it may be mediated by
a prevalence of anxiogenic-like AMY inputs on NAS,
like in mPFC inhibition, considering that facilitator
effect of NAS-Hip pathways on frontocortical inputs
has been described [28, 29, 49, 50, 52]. In the inverse
way, the AMY blockade led to increases like those
observed when the VH was stimulated by inner can-
nula and saline injection, suggesting the same interac-
tions previously described [28, 29, 49, 50, 52].
As it was previously said, NAS has been early in-
volved in anxiety processes by us and another group
[37, 44, 45], and after it, an important number of labo-
ratories are showing additional evidences on the role
of NAS in anxiety, citing our findings [12, 15, 16, 43,
65]. All these studies give support to a previous study
using immunohistochemical staining for fos-like ac-
tivity, mapping functional activation of discrete brain
areas induced by anxiogenic situations. In this previ-
ous study in rats, more stressing situations (plus maze
and footshocks) activated PFC, AMY and NAS, and
lower stressors (air puff) did not activate NAS fos-
like activity, suggesting a necessary degree of stress to
activate it [18]. The interactions between limbic and
striatal structures has been described and mainly re-
lated to pathways from AMY to NAS [11]. However,
as it was previously suggested [9], other pathways
connecting the involved areas could be acting in these
processes [8, 35, 36] and cannot be excluded. An an-
xiolytic effect mediated by glutamatergic projections
from PFC to AMY stimulating accumbal GABAergic
neurons has also been described [30, 34, 35]. The ef-
fect of PFC inhibition induced here by benzodi-
azepine injection could explain the anxiogenic-like
effect observed, with a decrease in time per entry.
Furthermore, short circuitries could be involved
within the studied structures, like those described
within AMY for CRH pathways [20].
Another relevant point to be considered is the fact
that in present study an important volume (1 µl) was
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used, aiming to reach the whole structures. This vol-
ume allows us to have clear and predictable results,
mainly in AMY and PFC. Several previous studies
have signaled the role of discrete nucleus within the
brain zones here involved. It is the case of AMY [46,
47, 57, 61, 62] and PFC [35, 39]. In future studies, the
role of these nuclei would be studied. In the present
paper our intention is to delimitate the effects exerted
byBDZ in the whole structures.
All these present evidences allow us to think that
present findings could be correlated with previously
described circuitries interactions, like those described
for AMY and PFC circuitries [9], AMY and NAS
[11], and AMY, PFC, Hip and NAS [28, 29, 49, 50,
52]. Like it was previously said, an activation of
AMY, Hip and some zones of PFC has been corre-
lated with stress arousal and its correlative anxiety
[63]. Recent conceptualizations consider previously
postulated hierarchical structure in a different way
that conceived by Jackson following levels of evolu-
tion of the nervous system, in which each level has
complete somatic representation. New higher levels
do not keep down lower ones. Today, it is considered
that new levels are integrated in a schedule in which
inputs are processed in distinct processing channels
[17, 64]. Furthermore, outputs of different brain lev-
els, such as FC, AMY and Hip are integrated within
NAS as different and integrating inputs, and coordi-
nating complex functions [28], such as those involved
in anxiety. These findings give additional support to
the idea that NAS is not only related to reward, but
also to responses to processing of environmental
stimulus, such as pleasant and unpleasant stimuli, as it
has been reported in humans using functional mag-
netic resonance images (fMRI) [40]. Animal and hu-
man studies appear to support the idea that this nu-
cleus is related to complex and sophisticated func-
tions, explaining its importance and role in human
illness. However, the involvement of additional cir-
cuitries cannot be ruled out.
Clinically, present basic findings could lead to
a better understanding of benzodiazepines therapeutic
and paradoxical effects, such as behavioral disinhibi-
tion and hostility rage reactions. These collateral ef-
fects have been previously reported in some studies
a long time ago [3, 27, 48], and some authors attrib-
uted them to several factors such as dosage, time ad-
ministration, psychopathological and medical condi-
tion and individual variables [3, 48]. The inhibition
prevalence on different structures here studied could
lead to anxiogenic or anxiolytic effects induced by
benzodiazepines, as it was observed in present results.
Additionally, present findings could give an inter-
pretation about some phenomena present in schizo-
phrenia, in which these circuitries are dysfunctioned
[25, 28, 29]. It has been described an emotional driv-
ing disturbance in schizophrenia [28], and it has been
attributed to a Hip failure to gate PFC inputs to NAS,
leading to an AMY inputs prevalence [28]. We have
previously observed that a glutamatergic blockade de-
crease anxiety. We have also suggested that this effect
in anxiety could be interpreted as a homologous sign
of schizophrenic affective flattening, since a decrease
in anxiety could be considered as a certain level of in-
difference coping by an anxiogenic stimulus [44]. We
have induced some schizophrenic homologous signs
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Tab. 1. Schematic results presentation: Time spent in the open arms (TSOA), time per entry (TPE), open arm entries (OAE), closed arm entries
(CAE), open/closed arm entries (OCAQ) and extreme arrivals (EA). All parameters studied are here considered, and the arrow number is indi-
cating significance levels obtained in the experiments compared to control (correspondence of one arrow by one asterisk; ­ p < 0.05, ­­ p <
0.01, ­­­ p < 0.001). Direction of the arrow is indicating if the values were increasing (­) or decreasing (¯) when compared to respective con-
trols. The negative sign is indicating absence of significance
Studied parameters Experiment 1
Chl AMY
Experiment 2
Chl mPFC
Experiment 3
Chl VH
Experiment 4
Saline groups
Experiment 5
Inj. cann. and saline
TSOA – ­­ – – ¯ – – ­­­ ­­­ ­­­
TPE – – ¯ ¯ – – – – – –
OAE – ­­ – – ¯ – – ­­­ ­­ ­­­
CAE – – – – – – – – – –
OCAQ – – – – ¯ – – ­­­ – –
EA – ­­ – – – – – ­­­ ­­ ­­­
in animals, suggesting that a glutamatergic dysfunc-
tion within NAS is related to positive [2, 21, 23–25,
45] and negative [23, 24, 44] symptoms, and also, to
working memory schizophrenic dysfunction [4].
These later findings are in accordance with the fact
that NAS is considered today a switchboard for goal-
directed behaviors [32]. Pharmacological glutamater-
gic NAS blockade induced an increase in PFC activity
[4], in accordance to other evidences showing that
a disinhibited prefrontal cortex impairs cognitive
flexibility [31]. Present results give a wider view
about these facts, studying separately the effects of
projecting structures to NAS in anxiety levels. In this
task in the elevated plus maze, anxiety levels and ex-
ploratory strategies are present and playing recipro-
callyin the same instance.
We conclude that the injection of dipotassium chlo-
razepate has a differential profile depending of the
brain area in which it is acting, leading to anxiolytic
effects (mediated by its injection within AMY) or
anxiogenic effects (mediated by its administration
within PFC or Hip). Anxiogenic effects could mediate
paradoxical effects induced by benzodiazepines. In
this way, facilitative and inhibitory effect on anxiety
processing appears to depend on benzodiazepines ac-
tion in specific brain areas.
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